(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report.
Recently, positron emission tomography (PET) imaging using PSMA-ligands has gained high attention as a promising new radiotracer in patients with prostate cancer (PC). Several studies promise accurate staging of primary prostate cancer and restaging after biochemical recurrence with (68)Ga-PSMA ligand Positron emission tomography/computed tomography (PET/CT). However, prospective trials and clinical guidelines for this new technique are still missing. Therefore, we summarized our experience with (68)Ga-PSMA ligand PET/CT examinations in patients with primary PC and biochemical recurrence. It focuses on the technical and logistical aspects of (68)Ga-PSMA ligand PET/CT examination as well as on the specific background for image reading discussing also potential pitfalls. Further, it includes relevant issues on free-text as well as structured reporting used in daily clinical routine.
Klinikum rechts der Isar, Department of Nuclear Medicine, Technische Universität München, Ismaninger Str. 22, 81675, Munich, Germany. isabel.rauscher@tum.de.|Clinical Cancer Center Munich (CCM), Munich, Germany. isabel.rauscher@tum.de.|German Cancer Consortium (DKTK), Heidelberg, Germany. isabel.rauscher@tum.de.
Isabel
I
Rauscher
Clinical Cancer Center Munich (CCM), Munich, Germany.|Klinikum rechts der Isar, Department of Urology, Technische Universität München, Ismaninger Str. 22, 81675, Munich, Germany.
Tobias
T
Maurer
Clinical Cancer Center Munich (CCM), Munich, Germany.|Department of Nuclear Medicine, Ludwig-Maximilians University of Munich, Marchioninistrasse 15, 81377, Munich, Germany.
Wolfgang P
WP
Fendler
Clinical Cancer Center Munich (CCM), Munich, Germany.|Grosshadern Campus, Department of Clinical Radiology, Ludwig-Maximilians University of Munich, Marchioninistrasse 15, 81377, Munich, Germany.
Wieland H
WH
Sommer
Klinikum rechts der Isar, Department of Nuclear Medicine, Technische Universität München, Ismaninger Str. 22, 81675, Munich, Germany.|Clinical Cancer Center Munich (CCM), Munich, Germany.|German Cancer Consortium (DKTK), Heidelberg, Germany.
Markus
M
Schwaiger
Klinikum rechts der Isar, Department of Nuclear Medicine, Technische Universität München, Ismaninger Str. 22, 81675, Munich, Germany.|Clinical Cancer Center Munich (CCM), Munich, Germany.|German Cancer Consortium (DKTK), Heidelberg, Germany.
Matthias
M
Eiber
D004492:Edetic Acid / Q000031:analogs & derivatives*; D005709:Gallium Isotopes; D005710:Gallium Radioisotopes; D006801:Humans; D007090:Image Interpretation, Computer-Assisted / Q000379:methods*; D008297:Male; D008499:Medical Records; D009842:Oligopeptides; D000072078:Positron Emission Tomography Computed Tomography / Q000379:methods*; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging*; D019275:Radiopharmaceuticals
D005709:Gallium Isotopes; D005710:Gallium Radioisotopes; D009842:Oligopeptides; D019275:Radiopharmaceuticals; C000718244:gallium 68 PSMA-11; D004492:Edetic Acid
Positron emission tomography; Prostate cancer; Prostate specific membrane antigen